BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17855486)

  • 1. Multiple myeloma: charging toward a bright future.
    Katzel JA; Hari P; Vesole DH
    CA Cancer J Clin; 2007; 57(5):301-18. PubMed ID: 17855486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the management of multiple myeloma.
    Kumar L; Verma R; Radhakrishnan VR
    Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
    Björkstrand B; Gahrton G
    Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapies in myeloma.
    Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
    Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
    Lonial S; Cavenagh J
    Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted treatments to improve stem cell outcome: old and new drugs.
    Raab MS; Breitkreutz I; Anderson KC
    Bone Marrow Transplant; 2007 Dec; 40(12):1129-37. PubMed ID: 17768392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NCCN: Multiple myeloma.
    Traynor AE; Noga SJ;
    Cancer Control; 2001; 8(6 Suppl 2):78-87. PubMed ID: 11760563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of central nervous system myeloma in the era of novel agents.
    Gangatharan SA; Carney DA; Prince HM; Wolf MM; Januszewicz EH; Ritchie DS; Harrison SJ
    Hematol Oncol; 2012 Dec; 30(4):170-4. PubMed ID: 22144117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial therapy in multiple myeloma: investigating the new treatment paradigm.
    Kettle JK; Finkbiner KL; Klenke SE; Baker RD; Henry DW; Williams CB
    J Oncol Pharm Pract; 2009 Sep; 15(3):131-41. PubMed ID: 19276138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):343-60. PubMed ID: 16503852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma--an update on diagnosis and treatment.
    Caers J; Vande broek I; De Raeve H; Michaux L; Trullemans F; Schots R; Van Camp B; Vanderkerken K
    Eur J Haematol; 2008 Nov; 81(5):329-43. PubMed ID: 18637123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
    Rajkumar SV; Buadi F
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten years of improvement in the management of multiple myeloma: 2000-2010.
    Harousseau JL
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):424-42. PubMed ID: 21156460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical updates and nursing considerations for patients with multiple myeloma.
    Faiman B
    Clin J Oncol Nurs; 2007 Dec; 11(6):831-40. PubMed ID: 18063542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of novel therapeutic targets for multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Anderson KC
    J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.